TY - JOUR
T1 - SATB1 gene expression and breast cancer prognosis
AU - Hanker, Lars C.
AU - Karn, Thomas
AU - Mavrova-Risteska, Loreta
AU - Ruckhäberle, Eugen
AU - Gaetje, Regine
AU - Holtrich, Uwe
AU - Kaufmann, Manfred
AU - Rody, Achim
AU - Wiegratz, Inka
N1 - Funding Information:
We thank Samira Adel and Katherina Kourtis for expert technical assistance. This work was supported by grants from the Deutsche Krebshilfe, Bonn , the Margarete Bonifer-Stiftung, Bad Soden , the BANSS-Stiftung, Biedenkopf , and the Dr. Robert Pfleger-Stiftung, Bamberg . The funding sources had no roles in the design of the study, analysis and interpretation of the data and writing of the manuscript.
PY - 2011/8
Y1 - 2011/8
N2 - Recently it has been shown that the genome organizer SATB1 plays an important role in breast cancer progression and predicts a poor prognosis. However its prognostic value compared to markers as the estrogen receptor is currently unclear. The expression levels of SATB1 mRNA from Affymetrix microarray in a cohort of 2058 breast cancer samples and its prognostic impact were analyzed. There was no significant difference in disease-free survival among ER negative cancers but instead a benefit for high SATB1 expression among ER positive tumors (p = 0.042). However, even in ER positive cancer no independent prognostic value in multivariate analysis with standard parameters was observed. Thus the use of SATB1 as target or prognostic marker for breast cancer should be viewed with caution and a possible confounding effect of the estrogen receptor status of the tumor should be taken into account when analysing new markers as SATB1.
AB - Recently it has been shown that the genome organizer SATB1 plays an important role in breast cancer progression and predicts a poor prognosis. However its prognostic value compared to markers as the estrogen receptor is currently unclear. The expression levels of SATB1 mRNA from Affymetrix microarray in a cohort of 2058 breast cancer samples and its prognostic impact were analyzed. There was no significant difference in disease-free survival among ER negative cancers but instead a benefit for high SATB1 expression among ER positive tumors (p = 0.042). However, even in ER positive cancer no independent prognostic value in multivariate analysis with standard parameters was observed. Thus the use of SATB1 as target or prognostic marker for breast cancer should be viewed with caution and a possible confounding effect of the estrogen receptor status of the tumor should be taken into account when analysing new markers as SATB1.
UR - http://www.scopus.com/inward/record.url?scp=79960570808&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2010.10.002
DO - 10.1016/j.breast.2010.10.002
M3 - Journal articles
C2 - 20980149
AN - SCOPUS:79960570808
SN - 0960-9776
VL - 20
SP - 309
EP - 313
JO - Breast
JF - Breast
IS - 4
ER -
